Poster Title
P-27 Design of a Novel Isoxazoline Class Drug for the Suppressive Treatment of Malaria
Abstract
Design of a novel isoxazoline class drug for the suppressive treatment of erythrocytic malaria through the inhibition of Plasmodium Falciparum Gylceraldehyde-3-phosphate Dehydrogenase (PfGAPDH) gave rise to creation of a synthetic plan for the proposed target molecule, α-amino-3-bromo-4,5-dihydroisoxazol-5-yl propionic acid. A literature-based analysis of the moieties targeting the PfGADPH active site led to the design of the target molecule. Subsequently, an exploration of the literature yielded a possible bifold synthetic plan. Attempts at a model epoxidation reaction using mCPBA were shown to be successful using mass spectrometry. Further efforts towards the synthesis of a 3-bromoisoxazoline will be described.
Start Date
2-28-2020 2:30 PM
P-27 Design of a Novel Isoxazoline Class Drug for the Suppressive Treatment of Malaria
Design of a novel isoxazoline class drug for the suppressive treatment of erythrocytic malaria through the inhibition of Plasmodium Falciparum Gylceraldehyde-3-phosphate Dehydrogenase (PfGAPDH) gave rise to creation of a synthetic plan for the proposed target molecule, α-amino-3-bromo-4,5-dihydroisoxazol-5-yl propionic acid. A literature-based analysis of the moieties targeting the PfGADPH active site led to the design of the target molecule. Subsequently, an exploration of the literature yielded a possible bifold synthetic plan. Attempts at a model epoxidation reaction using mCPBA were shown to be successful using mass spectrometry. Further efforts towards the synthesis of a 3-bromoisoxazoline will be described.
Acknowledgments
J.N. Andrews Honors Scholar
Mentor: Lisa Ahlberg, Chemistry & Biochemistry